Microbiomes Market to Grow by USD 824.3 Million (2025-2029) with Rising Disease Prevalence Boosting the Market, Report on How AI is Redefining Market Landscape - Technavio

NEW YORK, Feb. 6, 2025 /PRNewswire/ -- Report with market evolution powered by AI - The global microbiomes market size is estimated to grow by USD 824.3 million from 2025-2029, according to Technavio. The market is estimated to grow at a CAGR of over 18.3%  during the forecast period. Increasing prevalence of diseases is driving market growth, with a trend towards significant number of collaborations for developing microbiome therapeutics. However, challenges related to manufacturing and formulation of microbiome therapeutic products  poses a challenge. Key market players include AOBiome LLC, BiomX Inc., DuPont de Nemours Inc., Eligo Bioscience, ENTEROME SA, ExeGi Pharma, Ferring BV, MaaT Pharma, OraSure Technologies Inc., Osel Inc., Pendulum Therapeutics Inc., PureTech Health Plc, Qualigen Therapeutics Inc., Second Genome Therapeutics, Seres Therapeutics Inc., Synlogic Inc., Takeda Pharmaceutical Co. Ltd., Theriva Biologics Inc., Vedanta Biosciences Inc., and YSOPIA Bioscience.

Key insights into market evolution with AI-powered analysis. Explore trends, segmentation, and growth drivers- View Free Sample PDF

Market Driver

The Microbiomes Market is experiencing significant growth, particularly in the area of IBS-D and IBS-C. Fecal microbiota therapy (FMT) and therapeutic agents are trending in medical care for treating recurring Clostridium difficile infections. Phases I and II trials are underway for new therapeutics, including novel drugs and antimicrobial resistance genes. The pipeline with strategic collaborations in Gi indications, infections, and metabolic disorders. The application niche includes personalized therapies based on dietary recommendations, genomics, and immunity. Emerging revenue pockets include microbiome analysis for mental health, gut health, and human microbiome research. Value chain optimization is crucial due to the financial burden of chronic diseases and research and development in microbiome-based therapeutics for obesity, diabetes, and autoimmune disorders. Prebiotics and prebiotic supplements are also gaining popularity in the lifestyle-related diseases segment. Sequencing technologies are driving innovation in this space. 

Vendors in the microbiomes market are prioritizing collaborations as their key strategy for product development and expansion. By partnering with other companies, they gain access to advanced technologies and broaden their product offerings, which are often in the clinical trial or research stages. These collaborations also facilitate cross-selling opportunities and enable vendors to enter new markets. Notably, large pharmaceutical companies are increasingly collaborating with vendors to leverage microbiome therapies' potential in treating complex diseases such as cancer and Inflammatory Bowel Disease (IBD). For instance, Ferring Pharmaceutical, Rebiotix, and MyBiotics joined forces in February 2021 to develop live microbiome-based therapeutics for reproductive medicine and maternal health. 

Request Sample of our comprehensive report now to stay ahead in the AI-driven market evolution!

 Market Challenges

• The Microbiomes Market is witnessing significant growth due to the increasing prevalence of gastrointestinal disorders such as IBS-D and IBS-C. The market is focused on developing therapeutic agents like Fecal Microbiota Therapy (FMT) for medical care, especially for recurring Clostridium difficile infections. However, challenges such as antimicrobial resistance genes and high treatment costs remain. Companies are in various developmental stages, from Phase I to Phase II, working on novel drugs and microbial therapies for Gi indications. Strategic collaborations and research in gut microbiota, immunity, and personalized therapies are key trends. Emerging revenue pockets include metabolic disorders, mental health, and microbiome-based therapeutics for obesity, diabetes, and chronic diseases. Production analysis, dietary recommendations, and genomics are also crucial areas of focus. The value chain optimization and financial burden are significant concerns, making research and development in prebiotics, probiotics, and sequencing technologies essential.
• Microbiome product manufacturers encounter various complexities during the clinical development, manufacturing, and technology aspects of their businesses. These challenges include creating stable engraftments, discovering relevant biosensors, producing gene circuits, maintaining safety and bio-contentment standards, and efficiently designing microbial therapies. Vendors often face hurdles in culturing microorganisms during the research and development of drug candidates. Specifically, isolating, screening, and upscaling specific strains or species present difficulties. Furthermore, the downstream processing of the culture used in producing microbiome-based therapeutic and diagnostic products remains an unexplored area, adding to the complexity of the process.

Discover how AI is revolutionizing market trends- Get your access now!

Segment Overview 

This microbiomes market report extensively covers market segmentation by  

• Product
• Probiotics
• Foods
• Prebiotics
• Medical Food
• Others
• Application
• Therapeutics
• Diagnostics
• Geography
• North America
• Europe
• Asia
• Rest Of World (ROW)
• Disease
• Infectious
• Gastrointestinal
• Endocrine & Metabolic
• Type
• BCT/FMT
• Live Biotherapeutics

1.1 Probiotics- The microbiomes market is witnessing significant growth due to the increasing use of probiotics, particularly those containing beneficial bacteria. Probiotics, such as those from the Bifidobacterium, Bacillus, Saccharomyces species, and Lactobacillaceae family, are gaining popularity for their health benefits. These microbes are used to improve gut health and alleviate symptoms of conditions like irritable bowel syndrome (IBS) and inflammatory bowel disease. For instance, Bifidobacterium infantis 35624 is an effective probiotic strain for individuals with IBS, reducing abdominal pain, bloating, and gas. Other strains of Bifidobacterium offer additional benefits, such as lowering the risk of necrotizing enterocolitis in infants, preventing post-antibiotic diarrhea, and inhibiting the growth of harmful bacteria. Additionally, some probiotic products focus on non-bacterial microorganisms, like Saccharomyces boulardii CNCM I-745, which is a yeast used to prevent antibiotics-associated diarrhea due to its resistance to antibiotics. The expanding research on probiotics is expected to fuel the growth of this market segment during the forecast period.

Download a Sample of our comprehensive report today to discover how AI-driven innovations are reshaping competitive dynamics

Research Analysis

The Microbiomes Market is witnessing significant innovation in therapeutics, driven by the growing understanding of the role of the human microbiome in health and disease. Clinical trials are underway for therapeutics drugs targeting various microbiome-related conditions, including Inflammatory Bowel Disease (IBD) and chronic diseases. Diagnostics companies are developing advanced tests for gut health assessment, while personalized medicine approaches are gaining popularity based on microbiome composition and diversity. Prebiotics and probiotics are being engineered for targeted interventions, and fecal transplantation is showing promise for treating related diseases. Drug development is focusing on advanced drugs that manipulate the microbiome to improve immune system function and address drug interactions. Sequencing technology is enabling the exploration of the microbiome's complexities, leading to new therapeutic opportunities and the gut-brain axis. Investment in microbiome research is surging, with a strong pipeline of potential treatments and diagnostics.

Market Research Overview

The Microbiomes Market is a rapidly growing sector in healthcare, focusing on the development of therapeutics for various indications, including IBS-D and IBS-C. Fecal microbiota therapy (FMT) and other microbial therapies are at the forefront of this field, with several therapeutic agents in different developmental stages. Phase I and II trials are underway for the treatment of Clostridium difficile infection (CDI), recurring CDI, and other gastrointestinal infections. The pipeline, with a focus on novel drugs and strategic collaborations. Antimicrobial resistance genes pose a challenge, but research and development in this area is ongoing. The market also includes applications in metabolic disorders, mental health, and autoimmune disorders. Production analysis, dietary recommendations, genomics, and sequencing technologies are key areas of focus for value chain optimization. The financial burden of chronic diseases and the potential of personalized therapies are driving emerging revenue pockets. Prebiotics, probiotics, and microbiome-based therapeutics are gaining popularity for gut health, digestive wellness, and obesity management. The human microbiome holds immense potential for treating chronic diseases and improving immunity.

Table of Contents:

1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation

• Product
• Probiotics
• Foods
• Prebiotics
• Medical Food
• Others
• Application
• Therapeutics
• Diagnostics
• Geography
• North America
• Europe
• Asia
• Rest Of World (ROW)
• Disease
• Infectious
• Gastrointestinal
• Endocrine & Metabolic
• Type
• BCT/FMT
• Live Biotherapeutics

7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Trends
10 Company Landscape
11 Company Analysis
12 Appendix

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/

SOURCE Technavio